$4.13
-0.06[-1.43%]
At close: May 1
$4.13
0[0.00%]
PreMarket: 4:18PM EDT
Eagle Pharmaceuticals
(NASDAQ:EGRX)Latest News for Eagle Pharmaceuticals Stock (NASDAQ:EGRX)
Eagle Pharmaceuticals Stock (NASDAQ: EGRX)
Categories: All
Friday, April 12, 2024
Thursday, January 18, 2024
Wednesday, December 06, 2023
Thursday, November 30, 2023
Wednesday, November 29, 2023
- Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Nov 29, 2023, 2:02PM
- Why Is Eagle Pharmaceuticals Stock Trading Lower Today?Vandana Singh - Nov 29, 2023, 1:46PM
- Eagle Pharmaceuticals shares are trading lower after the company announced it received notification of deficiency from the Nasdaq regarding the requirement to timely file quarterly report on Form 10-Q. Also, Founder, President and CEO Scott Tarriff announced his resignation effective immediately.Benzinga Newsdesk - Nov 29, 2023, 12:51PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Nov 29, 2023, 12:31PM
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga Insights - Nov 29, 2023, 8:06AM
- Eagle Pharmaceuticals Receives Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-QBenzinga Newsdesk - Nov 29, 2023, 7:36AM
- Eagle Pharmaceuticals Says Effective Immediately Scott Tarriff, Founder, President And CEO, Has Announced His Resignation And Retirement; Chairman Michael Graves To Serve As Interim Executive ChairmanBenzinga Newsdesk - Nov 29, 2023, 7:32AM
Friday, November 17, 2023
Tuesday, November 14, 2023
Monday, November 13, 2023
Thursday, November 09, 2023
- Eagle Pharmaceuticals shares are trading lower after the company announced it delayed its Q3 results to review potential adjustments relating to the reporting of sales of PEMFEXY prior to filling its Form 10-Q. Also, it expects to revise its FY23 guidanceBenzinga Newsdesk - Nov 9, 2023, 1:22PM
- Eagle Pharmaceuticals Delays Q3 2023 Results And Conference Call; Expects to File Its Form-10-Q By Nov. 14, 2023Benzinga Newsdesk - Nov 9, 2023, 8:31AM
Wednesday, November 01, 2023
Tuesday, October 24, 2023
Monday, October 23, 2023
Thursday, October 05, 2023
Thursday, September 28, 2023
Tuesday, September 19, 2023
Monday, September 11, 2023
Friday, September 08, 2023
Tuesday, August 29, 2023
- Stocks That Hit 52-Week Lows On TuesdayBenzinga Insights - Aug 29, 2023, 2:37PM
- Eagle Pharmaceuticals Announced A Type C Meeting With The FDA Agreeing On A Path Forward To Advance The Development Of EA-114 For Breast Cancer In Post-menopausal Women. Eagle Currently Anticipates Filing A New Drug Application For EA-114 In 2024Benzinga Newsdesk - Aug 29, 2023, 6:55AM
Thursday, August 17, 2023
Wednesday, August 09, 2023
Tuesday, August 08, 2023
- Eagle Pharmaceuticals Reiterates FY23 Adjusted EPS Guidance Of $4.40-$4.70 Vs. Consensus Of $4.34Benzinga Newsdesk - Aug 8, 2023, 6:54AM
- Eagle Pharmaceuticals Q2 Adjusted EPS $1.18 Beats $1.05 Estimate, Sales $64.65M Beat $59.35M EstimateBenzinga Newsdesk - Aug 8, 2023, 6:52AM
- Earnings Scheduled For August 8, 2023Benzinga Insights - Aug 8, 2023, 4:48AM
Monday, August 07, 2023
Monday, July 31, 2023
Friday, June 16, 2023
Thursday, June 15, 2023
Wednesday, June 14, 2023
Tuesday, June 06, 2023
Monday, June 05, 2023
Friday, May 19, 2023
Tuesday, May 16, 2023
Wednesday, May 10, 2023
Tuesday, May 09, 2023
- Eagle Pharmaceuticals shares are trading lower after the company reported Q1 financial results and reaffirmed guidance.Benzinga Newsdesk - May 9, 2023, 12:17PM
- Eagle Pharmaceuticals Reaffirms FY23 Adj. EPS Outlook $4.20 - $4.53 vs. $4.24 EstimateBenzinga Newsdesk - May 9, 2023, 6:53AM
- Eagle Pharmaceuticals Q1 Adj. EPS $1.26 Beats $1.05 Estimate, Sales $66.31M Beat $63.29M EstimateBenzinga Newsdesk - May 9, 2023, 6:51AM
- Earnings Scheduled For May 9, 2023Benzinga Insights - May 9, 2023, 6:03AM